Myer shares rally 16% after its best result since 2014

Nick Sundich Nick Sundich, March 9, 2023

Myer shares (ASX:MYR) rose 16% this morning and are up more than 160% in the last 12 months. 

The company has shrunk significantly over the years but appears to have right-sized itself, if its 1HY23 results are anything to go by. 

 

No time to do stock research, but you still want to invest?

 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 
Myer grows its profit by 101%

For the 6 months ending on January 28 2023, Myer recorded $1.9bn in overall revenue (up 24.2%) and an NPAT of $65m, the highest since 1HY23 and up 101%. 

The company paid a dividend of 4c per share as well as a 4c per share special dividend. 

It closed the period with a $267m net cash position (up $50m) and a favourable inventory position. 

Myer told shareholders shoppers had shrugged off the cost of living crisis (so far) and return to stores over the Christmas shopping period, including CBD stores. 

Although online sales declined by 9.8%, the $382.3m figure represents 31.5% 3-year CAGR growth and isn’t as sharp of a decline as other retailers. 

 

Myer shares are performing well

As we mentioned above, Myer shares gained 16% today and are up over 160% in 12 months. 

 

Myer (ASX:MYR) share price chart, log scale (Source: TradingView)

 

One holder of Myer shares who would be pleased is Solomon Lew. His investment vehicle Premier Investment now holds 25.79% of Myer shares, a figure that he recently topped up. 

 

Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
 
With price targets, buy ranges, stop loss levels and Sell alerts too.

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

Blog Categories

Get Our Top 5 ASX Stocks for FY26

Recent Posts

Imricor

Imricor Medical (ASX:IMR) FDA Approval Ignites Shares, but the Real Test Starts Now

FDA Approval Is a Big Win, Not the Finish Line Imricor Medical (ASX:IMR) received FDA clearance for its Vision-MR diagnostic…

nuclear energy

How Nuclear Energy Became the World’s Most Feared Energy Source

Why Nuclear Energy Still Scares Us and What Really Went Wrong Many investors may remember periods when nuclear energy captured…